X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Hoechst Marion: Operating margin Zooms - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 30, 2001

    Hoechst Marion: Operating margin Zooms

    Hoechst Marion Roussel Ltd (HMR) has posted a PBT of Rs 215 m, a rise of 47% inspite of 7% reduction in turnover. This rise was on the back of an 810 basis points improvement in operating profit margins of the company. The rise in operating margins was due to company's focus on strategic products, better efficiencies and reduction in operating expenses.

    (Rs m) 2QFY01 2QFY02 Change
    Sales 1,300 1,212 -6.8%
    Other Income 19 13 -31.6%
    Expenditure 1,132 969 -14.4%
    Operating Profit (EBDIT) 168 243 44.6%
    Operating Profit Margin (%) 12.9% 20.0% 55.1%
    Interest 13 4 -69.2%
    Depreciation 28 37 32.1%
    Profit before Tax 146 215 47.3%
    Extraordinary Expenses (VRS) (25) (45) 80.0%
    Tax 44 48 9.1%
    Profit after Tax/(Loss) 77 122 58.4%
    Net profit margin (%) 5.9% 10.1%  
    No. of Shares (eoy) (m) 23 23  
    Diluted Earnings per share* 13.4 21.2  
    P/E (at current price) 19.3  
    (*- annualised)      

    The company's product portfolio now includes a rather unique combination of old, mature brands as well as new products, which have met with remarkable success. Major strategic brands of the company viz Cardace (69 %), Allegra (26%) and Amaryl (58%) continued to grow at a healthy rate. Other mature brands of the company seem to have maintained their revenue contribution. While domestic sales as a whole has remained flat, exports have grown by 19%.

    The company's rationalisation of product portfolio in recent years has helped in reducing the DPCO exposure from around 60% to around 35% currently. Some of the strong brands from the company's stable like Avil, Daonil, Soframycin, Novalgin however, continue to be under DPCO coverage.

    At the current market price of Rs 410, the stock is trading at 15 times its expected earnings for FY02. The growth in the current year is expected to be fuelled by latest product introductions.The triggers for the stock in the near term are expected outsourcing by the parent company 6-8 months down the line, growth in strategic new products, further introduction of new products and expected dilution of DPCO. However, slowdown in topline is a cause of concern. While the strategic products have recorded good growth rates, it has slowed down compared to 1QFY02. Further, though the company currently has been able to command premium prices for its strategic products till date, it might face stiff price competition from domestic players. Thus, the operating margins might witness a downturn as product portfolio of the company matures.

     

     

    Equitymaster requests your view! Post a comment on "Hoechst Marion: Operating margin Zooms". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    SANOFI INDIA SHARE PRICE


    Aug 23, 2017 03:36 PM

    TRACK SANOFI INDIA

    • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    SANOFI INDIA - UNICHEM LAB COMPARISON

    Compare Company With Charts

    COMPARE SANOFI INDIA WITH

    MARKET STATS